Onyema Ogbuagu Biography and Profile

I am Dr. Onyema Ogbuagu, an Associate Professor of Medicine, in the clinician-educator track and Director of the HIV Clinical Trials program of the Yale AIDS Program, Section of Infectious Diseases of the Yale School of Medicine.

My clinical responsibilities include educating and training medical students, residents and infectious diseases fellows in various capacities in inpatient and outpatient settings; and through structured course work and other teaching sessions. As a faculty of the HIV training track of the Yale-Internal Medicine primary care program and for over 6 years as a faculty of the Human Resources for Health program in Rwanda, I have extensive experience with curriculum development, structuring of residency training programs, and mentoring residents and faculty. In Rwanda specifically, I have and continue to mentor medical residents and junior faculty in quality improvement and clinical research projects that are locally relevant and addressing important infectious diseases-related problems (particularly HIV/AIDS and antimicrobial resistance).

Furthermore, I have facilitated meaningful educational and research collaborations between faculty and trainees across institutions. As the program director of World Bank and HRSA-funded efforts supporting the Liberia College of Physicians and surgeons (LCPS)–run Internal medicine residency training program, I have overseen the selection and deployment of faculty to Liberia, and am responsible for educational programs and activities aimed at strengthening the residency training program. Overall, my expertise and collective experiences to date have positioned me to design and run successful projects around capacity building in low-resource settings including developing and implementing innovative and robust medical training and research programs for faculty, fellows, residents and students.

For 5 years now, I have been the Director of the Yale AIDS Program HIV clinical trials program, and a principal investigator on numerous pharmacokinetic, phase 2 and 3 safety and efficacy trials of novel antiviral compounds (HIV). More, recently, given the alarming rate of new infections among men who have sex with men (MSM), I have focused on HIV prevention trials including being a co-principal investigator on a Yale CIRA funded project, which has supported the formation of a cohort of men who have sex with men, who are at high risk for HIV and are engaged in HIV PrEP services in order to study the impact of substance use on retention in care and adherence to PrEP. I am also a lead investigator on the international DISCOVER trial evaluating TAF/FTC vs TDF/FTC for HIV prevention among MSM and transgender women.

In response to the COVID pandemic, I am Yale principal investigator on multiple investigational therapeutic and preventative clinical trials for COVID-19 including remdesivir (now FDA approved), leronlimab and remdesivir and tocilizumab combination therapy as well as the Pfizer/BioNTech Vaccine trial.

Dr. Onyema Ogbuagu Education & Training

  1. Fellowship – Yale School of Medicine (2012)
  2. Residency – Mount Sinai School of Medicine (2010)
  3. MBBCh – University of Calabar, Nigeria (2003)

Onyema Ogbuagu Honors & Recognitions

  1. Gerald H. Friedland Award for Outstanding International Research 2019: Connecticut Infectious Diseases Society (2019)
  2. Gerald H. Friedland Award for Outstanding International Research: Connecticut Infectious Diseases Society (2014)

Board Certifications

  1. AB of Internal Medicine, Infectious Disease (2012)

Onyema Ogbuagu Publications

  • Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. Ogbuagu O, Marshall BDL, Tiberio P, Ogunbajo A, Barakat L, Montgomery M, Almonte A, Wray T, Williams EC, Edelman EJ, Chan PA. Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. AIDS And Behavior 2019, 23:190-200.
  • Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study. Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study. Medicine 2018, 97:e13016.
  • Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Ogbuagu O. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Review Of Anti-infective Therapy 2016, 14:1113-1126.
  • Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Koff A, Goldberg C, Ogbuagu O. Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Annals Of Medicine 2017, 49:534-544.
  • Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion On Drug Metabolism & Toxicology 2016, 12:721-31.
  • Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’. Chabria S, Barakat L, Ogbuagu O. Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’. International Journal Of STD & AIDS 2016, 27:1026-9.
  • CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients. Tiberio PJ, Ogbuagu OE. CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients. AIDS Reviews 2015, 17:202-11.
  • Unusual presentation of disseminated Nocardia abscessus infection in a patient with AIDS. Sherbuk J, Saly D, Barakat L, Ogbuagu O. Unusual presentation of disseminated Nocardia abscessus infection in a patient with AIDS. BMJ Case Reports 2016, 2016.
  • Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary Health-Care Facility in Kigali, Rwanda. Carroll M, Rangaiahagari A, Musabeyezu E, Singer D, Ogbuagu O. Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary Health-Care Facility in Kigali, Rwanda. The American Journal Of Tropical Medicine And Hygiene 2016, 95:1277-1283.
  • Dolutegravir/rilpivirine for the treatment of HIV-1 infection. Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV/AIDS (Auckland, N.Z.) 2018, 10:215-224.
  • HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care 2018, 30:1282-1289.

Patient Care Organizations

  1. IDS Care Program
  2. Infectious Diseases
  3. Internal Medicine

– Onyema Ogbuagu Biography (Onyema Ogbuagu)

Nairagent Hottest 🔥